Is a scenario possible wherein the drug exposure achieved in clinical studies surpass or exceed than the exposure achieved in nonclinical toxicity studies conducted of appropriate duration?
And if so, is the dose selection flawed in that particular clinical study?
And to address that kind of a situation, should more nonclinical toxicity studies be performed that test a higher exposure than what is expected in humans?